1. Home
  2. NUVL vs GTLS Comparison

NUVL vs GTLS Comparison

Compare NUVL & GTLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

N/A

Current Price

$96.50

Market Cap

7.8B

Sector

Health Care

ML Signal

N/A

Logo Chart Industries Inc.

GTLS

Chart Industries Inc.

N/A

Current Price

$206.62

Market Cap

9.3B

Sector

Industrials

ML Signal

N/A

Company Overview

Basic Information
Metric
NUVL
GTLS
Founded
2017
1859
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Metal Fabrications
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
7.8B
9.3B
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
NUVL
GTLS
Price
$96.50
$206.62
Analyst Decision
Strong Buy
Hold
Analyst Count
15
11
Target Price
$135.33
$203.22
AVG Volume (30 Days)
449.1K
2.1M
Earning Date
05-07-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$17.24
Revenue Next Year
$1,165.56
$6.26
P/E Ratio
N/A
$240.25
Revenue Growth
N/A
N/A
52 Week Low
$55.54
$104.60
52 Week High
$113.02
$208.24

Technical Indicators

Market Signals
Indicator
NUVL
GTLS
Relative Strength Index (RSI) 39.83 46.04
Support Level $73.71 $206.55
Resistance Level $107.13 $207.59
Average True Range (ATR) 3.10 0.47
MACD -0.09 -0.04
Stochastic Oscillator 21.24 48.70

Price Performance

Historical Comparison
NUVL
GTLS

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

About GTLS Chart Industries Inc.

Chart Industries provides a variety of cryogenic equipment for storage, distribution, and other processes within the industrial gas and liquefied natural gas industries. It also provides natural gas processing solutions for the natural gas industry and specialty products that serve a variety of spaces, including hydrogen, biofuels, cannabis, and water treatment. The firm acquired Howden in a significant deal in early 2023, roughly doubling the size of the company. It plans to merge with Flowserve by the end of 2025.

Share on Social Networks: